Traumatic Brain Injury (TBI)
Psychedelics are being investigated for their potential therapeutic effects on Traumatic Brain Injury (TBI), a condition that frequently results in various physical and psychological impairments. Early preclinical studies suggest that these compounds may influence inflammatory responses, promote neuroplasticity, and enhance neurogenesis, offering new avenues for treatment.
What is Traumatic Brain Injury (TBI)?
Traumatic brain injury (TBI) occurs when an external force causes damage to the brain, leading to alterations in brain function. This can result from falls, sports injuries, or accidents, and TBI is characterised by a wide range of physical and psychological symptoms that can vary in severity.
TBI is classified into mild, moderate, and severe categories. Mild TBI, or concussion, is the most common form and accounts for the majority of cases. Symptoms can include headache, confusion, and mood disorders, while moderate to severe injuries often present with more pronounced cognitive deficits and physical complications.
Diagnosing TBI can be complex and is typically reliant on clinical assessments and neuroimaging techniques. Treatment approaches vary based on the severity of injury, with an emphasis on preventing secondary brain damage and facilitating rehabilitation.
Current Treatments
Treatment for TBI ranges from rest and over-the-counter pain relief in mild cases to emergency medical interventions and rehabilitation for moderate to severe TBI. There are currently no FDA-approved medications specifically for TBI; hence standard care focuses on symptom management and recovery support.
Psychedelic Effect Matrix
Systematic comparison of compound efficacy and evidence levels for Traumatic Brain Injury (TBI).
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Supported by animal studies demonstrating effects on neurogenesis and recovery post-TBI. | Medium | Moderate | Consistent |
| LSD Demonstrated potential in enhancing neuroplasticity, supported by preclinical research. | Medium | Moderate | Consistent |
| DMT Shows promise in modulating inflammation, as evidenced in animal model studies. | Medium | Moderate | Consistent |
| MDMA Has shown benefits in treating associated mental health disorders, relevant post-TBI. | Medium | Moderate | Moderate |
Psilocybin and Traumatic Brain Injury (TBI)
Psilocybin acts primarily through serotonin receptors and has been shown to promote neurogenesis and synaptic connectivity in the brain. Its ability to enhance neuroplasticity suggests that it may facilitate recovery from brain injuries by supporting the brain's structural repair and functional recovery mechanisms following TBI.
LSD and Traumatic Brain Injury (TBI)
LSD is noted for its potential to promote brain plasticity by increasing dendritic spine density. This action may foster the brain's capacity to adapt following injury, potentially improving cognitive outcomes in patients with TBI through enhanced synaptic resilience.
DMT and Traumatic Brain Injury (TBI)
DMT's interaction with serotonin receptors, particularly the sigma-1 receptors, is believed to help mitigate inflammation in the brain, a common consequence of TBI. By reducing inflammatory responses and promoting protective brain signalling, DMT may aid in the recovery process after injury.
MDMA and Traumatic Brain Injury (TBI)
MDMA has been documented to influence mood and emotional resilience, which is critical for individuals recovering from TBI. Additionally, its potential to support neuroplasticity may provide benefits in cognitive and emotional rehabilitation.
Key Insights
- 1
Mental health disorders are prevalent post-TBI, often exacerbating recovery challenges.
- 2
Early evidence suggests psychedelics can have physiological benefits, targeting inflammation and promoting brain repair mechanisms.
- 3
Research involving psychedelics remains primarily in preclinical phases, highlighting an area ripe for exploration.
Industrial Landscape
Key players in this space include Lobe Sciences, Wesana Health, Revive Therapeutics, and organisations engaged in the development of psychedelic treatments specifically aimed at addressing TBI-related symptoms and recovery through innovative protocols.
Quick Indicators
\"Ongoing clinical evaluations are investigating Traumatic Brain Injury (TBI) as a primary indication for various psychedelic compounds.\"
Key Organizations
4 ConnectedDelix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
MAPS
The description of the stakeholder
Lykos Therapeutics
Longer description of Lykos .. lorem ipsum ..
Leiden University
Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.
Prominent Researchers
1 LinkedConnected Evidence
The latest clinical data points and verified academic findings associated with Traumatic Brain Injury (TBI).